Jonathan Quick
Officer at Jade Biosciences, Inc. (JBIO) since April 2025
Jonathan Quick has filed 1 insider report with the SEC since May 2025, as officer at Jade Biosciences, Inc. (JBIO). The latest filing, on May 1, 2025, is a Form 3: Jonathan Quick became an insider at Jade Biosciences, Inc. (JBIO).
- Filings
- 1
- Companies
- 1
- Bought on market
- None
- Sold on market
- None
Companies where Jonathan Quick is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Officersince April 2025 | $15.87 | May 1, 2025 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
Other insiders at the same companies
- Mark EisnerJBIO
- Christopher W. CainJBIO
- Bradford D. DahmsJBIO
- Elizabeth BaltaJBIO
- Tom FrohlichJBIO
- Andrew James KingJBIO
- Fairmount Funds Management LLCJBIO
- Atlas Venture Fund XII, L.P.JBIO
- Erin LavelleJBIO
- Lawrence Otto KleinJBIO
- Eric DobmeierJBIO
- Hetal KocinskyJBIO
- Ra Capital Management, L.P.JBIO
Questions about Jonathan Quick
- What is Jonathan Quick's role at Jade Biosciences, Inc.?
- Jonathan Quick reports to the SEC as officer at Jade Biosciences, Inc. (JBIO), according to the latest filing on May 1, 2025.
- Has Jonathan Quick bought or sold stock recently?
- No open-market purchases or sales by Jonathan Quick are on file.
- How do I get alerts when Jonathan Quick files?
- Follow Jonathan Quick on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Jonathan Quick (SEC CIK 0001839008). Totals count each trade once, skipping amendments whose original is on file, from May 1, 2025 on. View on SEC EDGAR